Clinical Trial Update: Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating donor lymphocyte infusion with azacitidine to prevent relapse after stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Juvenile Myelomonocytic Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Donor Lymphocyte Infusion

Snippet

Sponsor: University of California, San Francisco | Conditions: Acute Myelogenous Leukemia, Acute Lymphoid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-10-12